drugset

drugset / Trial / NCT00351507

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

NCT00351507 ↗

Phase 3 Completed 10 enrolled Novartis Pharmaceuticals

RandomizedCrossoverDouble-blindTreatment

Summary

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

Timeline

Start: 2005-05
Primary completion: 2006-02
Completion: 2006-02

Publications

Dalla Man C, Bock G, Giesler PD, Serra DB, Ligueros Saylan M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care. 2009 Jan;32(1):14-8. doi: 10.2337/dc08-1512. Epub 2008 Oct 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vildagliptin	Other / unclassified	—	—

Indications